Funding
Funding not disclosed
Founders
Product
Problem
Current diagnostic methods for various diseases, including cancer and neurological disorders, often require invasive procedures or lack the sensitivity for early detection. This leads to delayed diagnoses, impacting patient prognosis and treatment efficacy.
Solution
Mirnax Biosens offers a non-invasive diagnostic platform utilizing liquid biopsy to detect specific genetic biomarkers. This technology enables early identification and prognosis of diseases such as colorectal cancer, prostate cancer, and Alzheimer's disease. The platform supports the development and validation of diagnostic kits for high-incidence pathologies, providing a more accessible and timely approach to disease management.
Target Audience
The primary customers are healthcare providers, diagnostic laboratories, and pharmaceutical companies seeking advanced, non-invasive diagnostic solutions for early disease detection and prognosis.
Features
- Liquid biopsy platform for non-invasive detection of genetic biomarkers.
- Patented one-step method for rapid diagnosis and clinical prognosis.
- Development of diagnostic kits for various conditions, including cancer (e.g., colon, prostate) and neurological disorders (e.g., Alzheimer's).
- Proprietary MiRNAX platform designed for broad applicability across different diseases.
- Validation services for diagnostic systems using traceable clinical samples.
- Capabilities for developing kits for high-incidence pathologies.